The increased incidence of the Delta variant of SARS-CoV-2 has caused a substantial surge in the utilization of monoclonal antibody (mAb) drugs, particularly in areas of the country with low vaccination rates. On September 13, HHS transitioned from a direct ordering process to a state/territory-coordinated distribution system similar to that used for the distribution of mAbs from November 2020 – February 2021. Weekly distribution amounts for each state/territory will be determined by HHS based on weekly reports of new COVID-19 cases and hospitalizations in addition to data on inventories and use submitted to the federal government. State/Territorial Health Departments will determine where product goes in their jurisdictions.

More information can be obtained at https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab-etesevimab/Pages/Update-13Sept21.aspx.